Back to Top

"One of today's leaders in investor relations and shareholder services"

Tag Archives: AXIM

SeeThruEquity Initiates Coverage On Medical Marijuana, Inc. Investment Company AXIM Biotech (OTC: AXIM) With A Target Price Of $17.00

SAN DIEGO, May 17, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC PINK: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM) received coverage initiation from SeeThruEquity, a leading independent equity research firm focused on smallcap and microcap public companies, with a price target of $17.00.

“We are thrilled to see a well respected Wall Street equities firm initiating coverage on AXIM Biotech,” said Dr. Stuart Titus, President and CEO of Medical Marijuana Inc. (OTC: MJNA).  “We have believed that AXIM would emerge as an up-and-coming biotech concern and quite excited about their cannabinoid research and pharmaceutical development activities.  It is thrilling to see the investment community taking notice of AXIM’s emerging story and perceiving future value for investors.”

The full research report is available here. Highlights from the report include:

Large market opportunity
The market …

Continue Reading

Posted in Client News| Tagged |
AXIM

Medical Cannabis-Based Gum Moves into Production for Clinical Trials

AXIM

As of May 2, 2017, one of the world leaders in cannabinoid research and development declared their product development partner, Quay Pharmaceuticals Ltd., also known as Quay Pharma, acquired a license from the British Home Office to continue research related to AXIM’s MedChew Rx® line of pharmaceutical chewing gum. This particular license allows the British-based pharmaceutical company to work with controlled drugs in order to continue with the development process of the product.

Currently, MedChew RX® is made with 5 mg of cannabidiol (CBD) as well as an equivalent dosage of tetrahydrocannabinol (THC). When the drug does hit the market, it’ll be used to treat pain and spasms in patients who have multiple sclerosis (MS). This particular condition is a degenerative disease that affects the central nervous system and disrupts how the brain and body communicate with one another. Current research published by the National Organization for the Reform …

Continue Reading

Posted in Articles| Tagged , , , |

Medical Marijuana, Inc. Major Investment AXIM Biotech Moves Forward With Development Of MedChew Rx Pharmaceutical Chewing Gum

SAN DIEGO, May 3, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc.’s (AXIM® Biotech) (OTC: AXIM) product development partner Quay Pharmaceuticals Ltd. (“Quay Pharma”) has obtained the relevant licenses from the British Home Office to import and work with the controlled drugs that are required to continue the development of AXIM MedChew Rx® pharmaceutical chewing gum products.

MedChew Rx® is being developed as a pharmaceutical drug to treat pain and spasticity associated with multiple sclerosis (MS). It is formulated with 5 mg of cannabidiol (CBD) and 5 mg of tetrahydrocannabinol (THC).

The value of the MS treatment market is estimated to reach $20 billion by 2024, according to research firm GlobalData. This growth is primarily driven by the continued development of new products and an increase in diagnosis rates across …

Continue Reading

Posted in Client News| Tagged , , , |
AXIM Biotechnologies, Inc.

AXIM Biotechnologies, Inc. and API Develop Marinol Alternative

AXIM Biotechnologies, Inc.

Medical marijuana has presented life-changing treatment options for patients around the world, but with strict laws in many regions preventing the use of such pharmaceutical alternatives, progress has been gradual. There is still significant stigma surrounding the effects of medical marijuana and its use in a clinical treatment setting. Despite the many positive studies associated with these products, opposition persists in many sectors of the market. Companies such as AXIM Biotechnologies, Inc. (OTCQX: AXIM) have long been at the forefront of medical marijuana research and development, facing opposition from lobbyists and other detractors who seek to keep the status quo within the pharmaceutical industry. Until recently, Insys Therapeutics was one of those companies.

In the past, Insys Therapeutics has been active in the opposition of general marijuana legalization, donating $500,000 to a group called Arizonans for Responsible Drug Policy in the summer of 2016. The group launched a campaign …

Continue Reading

Posted in Articles| Tagged , , , |

Bioequivalent Product to Marinol in the Works with AXIM Biotech at the Helm

AXIM Biotechnologies

In recent months, the medical benefits of cannabis have been all over the news. With reports that cannabis oil can reduce and even stop seizures, help patients with memory loss like dementia and Alzheimer’s, and even help to reduce pain associated with chronic illness, it makes sense that more and more biotech companies would be looking to get in on the market.

Earlier this week biotech newcomer AXIM Biotechnologies, Inc. (OTCQX: AXIM) announced that they would be teaming up with a United States based API (Active Pharmaceutical Ingredient) production company to further their production and creation of a dronabinol based functional chewing gum. AXIM is a forerunner in cannabinoid research and have been working for years to help develop solutions like Marinol, a gel capsule containing cannabinoid to help with things like nausea associated with AIDS treatment and chemotherapy.

About AXIM

AXIM has long been part of the cannabinoid …

Continue Reading

Posted in Articles| Tagged , , |

AXIM Biotech Cannabis Chewing Gum Plans to Enter General Pain Market

AXIM

According to the National Institute of Health, pain impacts more people in the United States than cancer, heart disease and diabetes. Research shows that chronic pain is the leading cause of long-term disability, and it is also the most common reason for entering the health care system. Despite the great financial and personal costs associated with pain, this is a significantly underserved market in the United States and around the world. While there are many prescription drugs available on the market for the treatment of pain, many are either ineffective at managing acute or chronic pain or come with debilitating side effects.

Pain and the Opioid Epidemic

Opioid addiction affects between 26.4 and 36 million people around the world each year. The opioid epidemic has reached global crisis levels, and world leaders have launched various initiatives to help reduce reliance on these highly addictive drugs. While opioids are often effective …

Continue Reading

Posted in Articles| Tagged , |